Suppression of invasion and migration by 7-hydroxystaurosporine(UCN-01), a new ant i-tumor agent

Abstract

Abstract: Aim and Methods To investigate the effect of UCN-01(7-hydroxystaurosporine)on cell migration and invasion ability of DU-145, an invasive human pro state cancer cell line.Results It was found that UCN-01 at no n-cytotoxic doses (100 nmol·L^-1)significantly inhibited prostate cancer DU-145 cell invasion and migration behaviors.Moreover, this anti-invasion and migration activity of UCN-01 was associated with an up-regulation of cell adhesion molecule E-cadherin.Conclusion These results indicate for first time that UCN-01 inhibits the invasion and migration of human prostate cancer cells.Thus, clinical application of UCN-01 may contribute to the potential benefit for suppression of prostate cancer invasion and metastasis.

Key words: 7-hydroxystaurosporine(UCN-0 1), prostate, tumor, invasion, migration

CLC Number:

R979.1

MENG Qing-Hui, SHAO Rong-Guang, XU Jing-Wen, FAN Sai-Jun. Suppression of invasion and migration by 7-hydroxystaurosporine(UCN-01), a new ant i-tumor agent[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(4): 289-293.

References

1 Caponigro F,French RC,Kay e S B.Protein kinase C:a worthwhile target for anticancer drugs ?Anti-cancer Drugs,1997;8:26
2 Gome z DE,Skilton G,Alonso DF,et al.The role of protein kinase C and novel phorbol ester receptors in tumor cell invasion and metastasis.Oncol Rep,1999;6:1363
3 Takahashi I,Kobayashi E,Asano K,et al.UCN-01,a selective inhibitor of protein kinase C from Strep tomyces.J Antibiot(Tokyo),1987;40:1782
4 Fan S,Meng Q.UC N-0 1 (7-hydroxystaurosporine):A profound an ti-cancer agent.Chin J Clin Phar macol Therap(in press)
5 Meng Q,Qi M,Chen DZ,et al.Suppression of breast cancer invasion and migration by indole-3-carbinol:associated with up-regulation of BRCA1 and E-cad-herin/catenin complexes.J Mo l Med,2000;78:155
6 Kruger EA,Blago sklonny M V,Dix on SC,et al.UCN-01,a protein kinase C inhibitor,inhibits en-dothelial cell proliferation and angiogenic hypoxicre-sponse.Invasion Metastasis,1998;18:209
7 Hendrix MJ,Seftor EA,Seftor RE,et al.A simple quantitative assay for studying the invasive potential of high and low human me tastatic variants.Cancer Lett,1987;38:137
8 Liu B,Maher RJ,Hannun YA,et al.12(S)-HE TE enhancement of prostate tumor cell invasion:selective role of PKC alpha.J N atl Cancer Inst,1994;86:1145
9 Timar J,Raso E,Fazakas ZS,et al.Multiple use of a signal transduction pathway in tumor cell invasion.Anticancer Res,1996;16:3299
10 Szaniawska B,Gawry chow ski K,Janik P.The effect of protein kinase C inhibitors on invasion of human ovary cancer cells.Neoplasma,1998;45:7
11 St am JC,Michiels F,Van der Kammen RA,et al.Invasion of T-lymphoma cells:cooperation between Rho family GTPases and lysophospholipid receptor signaling.Embo J,1998;17:4066
12 Shimao Y,Nabeshima K,Inoue T,et al.TPA-en-hanced motility and invasion in a highly metastatic variant (L-10)of human rectal adenocarcinoma cell line RCM-1:selective role of PKC-alpha and its inhibition by a combination of PDBu-induced PKC down-regulation and antisense oligonucleotides treatment.Clin Exp Me tastasis,1999;17:351
13 Hoe lting T,Duh QY,Clark OH,et al.Tamoxifen antagonizes prolife ration and invasion of estrogen receptor-negative metastatic follicular thyroid cancer cells via protein kinase C.Cancer Lett,1996;100:89
14 Zhang W,Law RE,Hinton DR,et al.Inhibition of human malignant glioma cell motility and invasion in vitro by hype ricin,a potent protein kinase C inhibitor.Cancer Lett,1997;120:31
15 Bracke ME,Van Roy FM,M are el MM.The E-cad-herin/catenin complex in invasion and metastasis.Curr Top Microbiol Immunol,1996;213:123
16 Zschiesche W,S chonborn I,Behrens J,et al.Expression of E-cadherin and catenins in invasive mammary carcinomas.Anticancer Res,1997;17:561
17 Bracke ME,Charlier C,Bruyneel EA,et al.Tamox-ifen re stores the E-cadher in function in human breast cancer M CF-7/6 cells and suppresses their invasive phenotype.Cancer Res,1994;54:4607

[1]	WANG Yan, ZHANG Jinhui, ZHAO Yongchen, LIU Hongxiang, LIU Yawei, MIAO Huanhuan, YANG Xincai. Sequoiaflavone inhibits stem cell properties such as proliferation and invasion of gastric cancer cells by down-regulating PI3K/AKT signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 508-513.
[2]	LI Yanyang, WANG Yunjiao, LV Shichao. Effects and mechanism of traditional Chinese medicine injection in prevention and treatment of cardiotoxicity induced by antineoplastic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 572-577.
[3]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[4]	WANG Siyu, LI Jiawei, LI Chenghao, LI Ling, GUO Qingyang, QIU Lu, ZHOU Shiqin, LIU Yongqi. Research progress of lactate dehydrogenase A in digestive system tumors and related drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 445-454.
[5]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[6]	WANG Dan, YAN Xiaoli, ZHANG Yuan. Helicobacter pylori infection influences the efficacy of immunotherapies for gastric cancer#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 228-234.
[7]	ZHANG Wei, WANG Hongyuan, LEI Xiaohang, ZHAO Yingshuai, LV Weichao, ZHANG Jianguo. BCG + piroxicam versus BCG + gemcitabine for prevention of postoperative recurrence in intermediate- and high-risk bladder cancer and effects on serum AGR and PON1 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1146-1153.
[8]	LIU Dan, LIU Ming, JIN Liangyou, PAN Juan, XIN Haoru, LIU Mengyuan, LI Xin, ZHENG Kun, FENG Xiaoling. Research progress on the antitumor activity of costunolide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1168-1176.
[9]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[10]	HUANG Hao, JIA Hong, WANG Xiaoshuang, ZHANG Lu, JIANG Hua. Effects of co-culture of dendritic cells loaded with MAGE-A3 antigen and cytokine-induced killer cells on tumor stem cells and malignant progression of endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 42-50.
[11]	GAO Lili, WANG Yuzhu, WANG Yan, LI Jian, WANG Jun. General considerations for clinical pharmacology of antitumor antibody-conjugated drugs: Implications from FDA review cases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 75-85.
[12]	LIU Jiajia, GAO Yan, ZHANG Yehui, WU Jing. Functions of CRABP2 in tumorigenesis and progression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 86-92.
[13]	HONG Ziqiang, GOU Wenxi, CUI Baiqiang, BAI Xiangdou, JIN Dacheng, GOU Yunjiu. Role of the m7G methyltransferase METTL1 in tumours [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 93-100.
[14]	WANG Yali, HUO Xulei, CHEN Feng, LI Shenglan, ZHENG Xiaohong, WANG Can, LI Wenbin. Research progress on the antitumor effect of nifurtimox [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 955-960.
[15]	SUI Yuxia, ZHUANG Jie, ZHUANG Min, HUANG Gui. Delicaflavone inhibits the invasion and migration of gefitinib-resistant lung cancer PC-9/GR cells by regulating epithelial-mesenchymal transition via PI3K/Akt/mTOR pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 614-621.